All News

A new meta-analysis links moderate-to-severe lower urinary tract symptoms (LUTS) to heart disease in men, possibly because unhealthy lifestyles boost the risks of both conditions.

"LUTS is an important health care burden, and health care professionals should be screening for its presence in men at risk," writes Steven A. Kaplan, MD.

In this interview, Angela B. Smith, MD, MS, discusses two work force problems in urology, discrepancies in male and female urologist compensation, and solutions for these issues.

A treatment system that uses steam to ablate prostate tissue (Rezūm, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.

This article provides an update on the risk factors for stone disease and its presentation in children, and offers practical tips on its evaluation, treatment, and prevention.

The literature is rife with information and data, sometimes conflicting, as to whether disclosure and defensive medicine are beneficial to reducing liability and the chances of a lawsuit. One reason for this conflicting data is that the health care system as a whole is in the midst of a massive change, going from an authoritative physician model to one in which patients are increasingly engaged in their own medical care and treatment decisions.

"The marriage process, regardless of age, requires careful thought about a number of financial situations a couple will likely face," write Joel M. Blau, CFP, and Ronald J. Paprocki, JD, CFP, CHBC.

The AUA and other organizations have been urging Congress to create transparency and accountability within the USPSTF while adding input and feedback from patients and specialists involved in treating the conditions for which it is developing recommendations.

In this blog post, urology resident Nirmish Singla, MD, discusses the hidden gains that quality improvement initiatives can offer. Read his blog post.

A bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.

A recent study of patients with a new diagnosis of microhematuria finds that rates of bladder and kidney cancer as well as urolithiasis depend on how thoroughly the patients are evaluated.

Results from a recent prospective trial suggest that active surveillance may be suitable for some patients with advanced renal cell carcinoma.

Steven Lamm, MD and Darren Sultan, BA look at this and several other misconceptions.

In her latest blog post, Adele M. Caruso, MSN, CRNP, discusses challenges related to bladder cancer surveillance and how they can be overcome.

Urologist Henry Rosevear, MD, recalls some of his experiences working with government-sponsored health care programs.

A study reporting an increase in the number of men initially presenting with metastatic prostate cancer has been the source of controversy since its July publication.

We spoke to Gerald L. Andriole, MD, Michael Koch, MD, Herbert Lepor, MD, Mani Menon, MD, and Joel Nelson, MD, about the highly anticipated study findings.

One urologist directs patients to the Johns Hopkins site, while another recommends the AUA homepage.

For men with high-risk pathology at radical prostatectomy, exposure to results of a genomic test that classifies 5-year risk of metastasis reduces decisional conflict, according to findings of a prospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.

In this interview, Mark A. Moyad, MD, MPH, discusses non-drug interventions for urologic conditions, the difference between prescription drugs and nutraceuticals, and why a heart-healthy diet is a prostate-healthy diet.

In an effort to increase access to health care providers for members of the military and veterans, federal agencies are seeking ways to expand telemedicine and practice authority for advanced practice registered nurses (APRNs).

"Avoiding unnecessary biopsies should be a high-priority goal for us all," writes J. Brantley Thrasher, MD.

An ongoing phase II trial investigating abiraterone acetate (ZYTIGA) and enzalutamide (XTANDI) as treatment for men with chemotherapy-naïve metastatic castrate-resistant prostate cancer is aiming to characterize the effects of these targeted hormonal therapies on cognition and mood.

Multiparametric magnetic resonance imaging (mpMRI) identifies a significant percentage of men who present with an elevated serum PSA level who may safely avoid prostate biopsy, British researchers report.

Here are the answers to frequently asked questions about the technical, financial, and ethical issues surrounding penile transplantation surgery.

Applicants to urology residency programs have clear ideas about what they are seeking in a training program and a good understanding of the factors influencing their rankings, according to the findings of a survey presented at the AUA annual meeting San Diego.

In this installment in a series on MACRA, I will review the definition of APMs, how participating providers would be reimbursed under MACRA (as proposed), and the relevance to specialists, including urologists.